US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,290.18

-42.4016-3.18%

Number of Gainers:- -

Number of Losers:3

Number of Flat:- -

PE:- -

High:1,334.03

Open:1,331.37

Low:1,289.35

Close:1,332.58

Loading ...

Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit

MT Newswires Live

U.S. Attorney in Manhattan Announces $202 Mln Settlement With Gilead Sciences for Using Speaker Programs to Pay Kickbacks to Doctors

THOMSON REUTERS

Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors

Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress

Simply Wall St.

Novartis reports Q1 core EPS $2.28, consensus $2.11

Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States

ACCESS Newswire

Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk

Novartis Surprises With Another Beat & Raise -- Market Talk

Sui Ecosystem Token Continues Bullish Trend, DEEP Surges Over 12.99% in 24 Hours

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Sui Ecosystem Token Continues to Surge, WAL Surges Over 16% in 24 Hours

US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies

MT Newswires Live

Gilead Shares Down 3.6% After Quarterly Revenue Miss

THOMSON REUTERS

Wall Street Analysts Are Bullish on Top Healthcare Picks

Gilead Shares Down 4.2% Premarket After Quarterly Revenue Miss

THOMSON REUTERS

Gilead : RBC Raises Target Price to $92 From $89

THOMSON REUTERS

Gilead Sciences (GILD) Gets a Buy from Oppenheimer

Sui Ecosystem Token Sees Widespread Price Surge, CETUS Up 36% in 24 Hours

Gilead Q1 Biktarvy Sales $3.15 Bln

THOMSON REUTERS

Gilead Outlook 2025 EPS $5.65 - $6.05 VS Prior Guidance $5.95 - $6.35

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4578/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1290.1827,"timestamp":1746561599999,"preClose":1332.5844,"halted":0,"volume":13777605,"delay":0,"changeRate":-0.031819,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-42.401611,"latestTime":"05-06 16:00:00 EDT","open":1331.366,"high":1334.0319,"low":1289.3517,"amount":1374915110.664747,"amplitude":0.033529,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746604800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.107338,"peRate":18.869411,"turnoverRate":0.004504,"increases":0,"decrements":3,"flats":0,"marketCap":340404298508,"floatMarketCap":321400086112},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1334.0319,"amplitude":0.033529,"preClose":1332.5844,"low":1289.3517,"pbRate":"6.107338","latestPrice":1290.1827,"volume":13777605,"delay":0,"open":1331.366,"prevYearClose":1164.883,"prevWeekClose":1345.7642,"prevMonthClose":1353.2946,"prevQuarterClose":1364.0579,"fiveDayClose":1341.6866,"twentyDayClose":1268.8196,"sixtyDayClose":1248.9824,"secType":"PLATE","market":"US","turnoverRate":0.004504,"peRate":18.869411,"marketCap":340404298508,"floatMarketCap":321400086112,"timestamp":1746561599999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":0,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531767764","title":"Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2531767764","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531767764?lang=en_us&edition=fundamental","pubTime":"2025-04-30 02:19","pubTimestamp":1745950748,"startTime":"0","endTime":"0","summary":"Gilead Sciences  has agreed to pay $202 million in the settlement of a civil fraud lawsuit accusing it of paying kickbacks to healthcare practitioners to promote its HIV treatment drugs, the US Attorney for the Southern District of New York said in a Tuesday statement.The illegal kickbacks caused false claims for Gilead's HIV drugs to be paid by federal healthcare programs, in violation of the False Claims Act, according to the statement.Under the settlement, Gilead agreed to pay a total sum of $202 million, of which around $176.9 million will be paid to the US and the remainder will be paid to various states.  As part of the settlement, the company also made extensive factual admissions regarding its conduct, the statement said.The settlement was approved Monday by US District Judge Paul Engelmayer.Gilead did not immediately reply to a request for comment from MT Newswires.Price: 106.17, Change: -0.17, Percent Change: -0.16","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4550","LU0109394709.USD","IE00B3T34201.USD","LU1066053197.SGD","IE0002270589.USD","LU1839511570.USD","BK4585","LU2468319806.SGD","LU0058720904.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","BK4588","LU0234570918.USD","LU0320765992.SGD","IE00BKVL7J92.USD","BK4578","BK4568","LU1585245621.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","BK4566","LU2087621335.USD","LU1066051498.USD","LU1571399168.USD","BK4139","BK4583","BK4532","GILD","LU0889565916.HKD","IE00B7SZLL34.SGD","LU1430594728.SGD","LU2089984988.USD"],"gpt_icon":0},{"id":"2531764556","title":"U.S. Attorney in Manhattan Announces $202 Mln Settlement With Gilead Sciences for Using Speaker Programs to Pay Kickbacks to Doctors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531764556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531764556?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:29","pubTimestamp":1745947786,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL1N3R7145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","LU1066053197.SGD","LU1066051498.USD","BK4568","BK4532","LU2087621335.USD","BK4566","LU1430594728.SGD","IE0002270589.USD","LU2468319806.SGD","LU1585245621.USD","GILD","IE00BZ1G4Q59.USD","BK4578","LU0320765992.SGD","IE00B3T34201.USD","BK4139","BK4585","BK4583","BK4550","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU0058720904.USD","LU2089984988.USD","LU0889565916.HKD","IE00BSNM7G36.USD","LU1839511570.USD","LU0289739699.SGD","IE00B7SZLL34.SGD","LU0234570918.USD","LU0109394709.USD","LU1571399168.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2531764206","title":"Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531764206","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531764206?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:29","pubTimestamp":1745947786,"startTime":"0","endTime":"0","summary":"Gilead Sciences reaches $202 million settlement with US over kickbacks to doctorsNEW YORK, April 29 (Reuters) - Gilead Sciences GILD.O has reached a $202 million settlement to resolve a civil fraud la","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL1N3R7145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","IE00B19Z3581.USD","LU1066053197.SGD","LU1066051498.USD","LU2468319806.SGD","IE00BSNM7G36.USD","BK4139","GILD","BK4550","IE00B19Z3B42.SGD","LU1585245621.USD","LU1430594728.SGD","IE00B7SZLL34.SGD","BK4585","LU0320765992.SGD","LU0109394709.USD","LU0289739699.SGD","LU1839511570.USD","BK4532","BK4583","BK4588","LU1571399168.USD","LU0234570918.USD","BK4566","LU2087621335.USD","LU2089984988.USD","IE00BZ1G4Q59.USD","BK4578","LU0058720904.USD","IE0002270589.USD","LU0889565916.HKD","IE00B3T34201.USD","BK4568"],"gpt_icon":0},{"id":"2531789793","title":"Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2531789793","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531789793?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:27","pubTimestamp":1745947636,"startTime":"0","endTime":"0","summary":"Gilead Sciences recently announced a presentation at the EASL Congress focusing on liver disease, with promising research in both hepatitis B and C. This comes alongside solid Q1 earnings results where a significant net income turnaround was noted. These developments, combined with a quarterly dividend declaration and ongoing share buybacks, potentially supported a 13% share price increase over the last quarter. Meanwhile, the general market showed strength with a 7% rise, suggesting Gilead's performance aligns with broader positive trends, further buoyed by robust earnings reports across various industries.We've identified 2 possible red flags with Gilead Sciences and understanding the impact should be part of your investment process.NasdaqGS:GILD Revenue & Expenses Breakdown as at Apr 2025. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-nasdaqgs-gild-showcases-172716096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU0234570918.USD","LU1066051498.USD","LU2089984988.USD","BK4532","LU1839511570.USD","LU2087621335.USD","LU0058720904.USD","IE00B19Z3B42.SGD","IE0002270589.USD","LU1571399168.USD","LU1066053197.SGD","IE00B19Z3581.USD","BK4550","BK4583","IE00BKVL7J92.USD","LU0109394709.USD","LU0889565916.HKD","LU1585245621.USD","BK4578","LU1430594728.SGD","IE00B7SZLL34.SGD","LU0289739699.SGD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","BK4566","IE00B3T34201.USD","BK4585","GILD","LU0320765992.SGD","BK4588","BK4568","LU2468319806.SGD"],"gpt_icon":0},{"id":"2531375103","title":"Novartis reports Q1 core EPS $2.28, consensus $2.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2531375103","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531375103?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:50","pubTimestamp":1745938234,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $13.23B, consensus $13.02B. Commenting on Q1 results, Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis has had a strong st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-reports-q1-core-eps-2-28-consensus-2-11?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-reports-q1-core-eps-2-28-consensus-2-11?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE0002141913.USD","BK4578","NVS","BK4007","BK4588","IE00B4R5TH58.HKD","LU0208291251.USD","BK4532","IE0009355771.USD","LU0070302665.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0211331839.USD","LU0320765489.SGD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2531775351","title":"Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2531775351","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531775351?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:35","pubTimestamp":1745930100,"startTime":"0","endTime":"0","summary":"NORTHAMPTON, MA / ACCESS Newswire / April 29, 2025 / Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch AIDSVu - an online mapping tool that visualizes granular data related to the HIV epidemic in the United States.The tool was designed to help increase awareness and understanding of the impact of HIV across the U.S., especially in the South.AIDSVu analyses have revealed that although new HIV diagnoses have been declining throughout the country from 2008 to 2022, this progress has been uneven across regions. For example, the U.S. South saw only a 17% decrease in new HIV diagnoses during this period compared to a 43% decrease in the Northeast.\"Data is power,\" he says. \"Whether you are a mathematical person or a visual person, you can come and look and we can have a common understanding of what the HIV epidemic looks like in our city, in our ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-aidsvu-online-mapping-123500779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","UBCP","BK4583","BK4532","LU2089984988.USD","IE00BKVL7J92.USD","LU1430594728.SGD","BK4585","LU1839511570.USD","LU2468319806.SGD","BK4139","LU1066051498.USD","IE00B19Z3B42.SGD","LU0058720904.USD","IE0002270589.USD","LU1585245621.USD","IE00BZ1G4Q59.USD","BK4568","LU0320765992.SGD","IE00B19Z3581.USD","BK4578","LU1066053197.SGD","LU0889565916.HKD","LU1571399168.USD","LU0234570918.USD","LU0289739699.SGD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","GILD","IE00B3T34201.USD","LU0109394709.USD","LU2087621335.USD","BK4588","BK4211","BK4550"],"gpt_icon":0},{"id":"2531782972","title":"Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2531782972","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531782972?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:47","pubTimestamp":1745927220,"startTime":"0","endTime":"0","summary":"1147 GMT - Novartis's 2025 guidance lift for both sales and profits should be well-received among investors, Jefferies analysts say in a note. The Swiss drugmaker's higher revenue, a better gross margin and lower R&D spend drove its core operating income above consensus, the analysts say. \"We believe we could see a continuing beat-and-raise story this year,\" they say. Shares rise 0.7% to 94.04 euros.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","BK4588","IE00BJJMRZ35.SGD","IE0009355771.USD","ISBC","NVS","LU0211331839.USD","LU0320765489.SGD","IE00BJT1NW94.SGD","BK4007","LU0070302665.USD","IE00BFTCPJ56.SGD","BK4211","LU0208291251.USD","BK4532","IE00B2B36J28.USD","IE0002141913.USD","BK4585","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2531783542","title":"Novartis Surprises With Another Beat & Raise -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2531783542","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531783542?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:42","pubTimestamp":1745923320,"startTime":"0","endTime":"0","summary":"1042 GMT - Novartis exceeded expectations with profit and sales figures, accompanied by an improved outlook, defying concerns about upcoming generic competition in the U.S. for three of its key products, Vontobel analyst Stefan Schneider says in a note. \"With the generic entry to three Novartis products still expected per mid-year, the guidance increase appears to us as a very confident sign that the company's growth drivers are expected to perform well also during the remainder of the year,\" he says. The Swiss drugmaker hereby signals that it can comfortably overcompensate the expected generic erosion, he says. Shares rise 1.1% to 94.43 euros. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","BK4007","LU0070302665.USD","BK4578","LU0320765489.SGD","BK4585","LU0208291251.USD","NVS","BK4532","IE00BFTCPJ56.SGD","LU0211331839.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE0002141913.USD","BK4588","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2531212982","title":"Sui Ecosystem Token Continues Bullish Trend, DEEP Surges Over 12.99% in 24 Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2531212982","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531212982?lang=en_us&edition=fundamental","pubTime":"2025-04-29 10:21","pubTimestamp":1745893260,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 29, according to GMGN market data, the Sui ecosystem's native tokens continued to surge, including:DEEP currently has a market capitalization of $6.95 billion, with a 24-hour increase of 12.99%;BLUE currently has a market capitalization of $39.5 million, with a 24-hour increase of 10.8%;NAVX currently has a market capitalization of $4.5 million, with a 24-hour increase of 7.29%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/291635","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BLUE","BK4578","DEEP","BK4139","BK4556"],"gpt_icon":0},{"id":"2531608266","title":"Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2531608266","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531608266?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:05","pubTimestamp":1745870700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 28, 2025----Contineum Therapeutics, Inc.  , a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology  indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company’s executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company’s Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/contineum-therapeutics-appoints-timothy-watkins-200500814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2468319806.SGD","QLD","IE00B7SZLL34.SGD","USAW.SI","LU0109394709.USD","BK4550","BK4532","IE00B19Z3B42.SGD","CTNM","LU2089984988.USD","IE00BKVL7J92.USD","PSQ","BK4585","LU1066051498.USD","USJW.SI","LU1571399168.USD","IE00B3T34201.USD","LU0058720904.USD","TSYW.SI","IE00B19Z3581.USD","GILD","IE00BSNM7G36.USD","LENZ","LU0320765992.SGD","LU1430594728.SGD","IE0002270589.USD","LU0234570918.USD","BK4588","IE00BZ1G4Q59.USD","NQmain","LU0889565916.HKD","BK4566","LU1585245621.USD",".IXIC","LU1839511570.USD","BK4578","BK4139","MNQmain","TQQQ","BK4568","NVIW.SI","BK4007","LU0289739699.SGD","LU1066053197.SGD","QID","SQQQ","LU2087621335.USD","BK4583"],"gpt_icon":1},{"id":"2530907164","title":"Sui Ecosystem Token Continues to Surge, WAL Surges Over 16% in 24 Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2530907164","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530907164?lang=en_us&edition=fundamental","pubTime":"2025-04-28 10:56","pubTimestamp":1745808960,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 28th, according to market data, the Sui ecosystem token continues to rise, including:WAL surged over 16% in the past 24 hours, now trading at $0.63;DEEP surged over 15% in the past 24 hours, now trading at $0.1996;BLUE surged over 13% in the past 24 hours, now trading at $0.1225;TURBOS surged over 9.5% in the past 24 hours, now trading at $0.00194.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/291484","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4211","WAL","LU0106831901.USD","BLUE","DEEP","LU1668664300.SGD","BK4139","BK4578","BK4585","BK4589","BK4588","BK4556","LU1791807156.HKD"],"gpt_icon":0},{"id":"2530643321","title":"US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2530643321","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530643321?lang=en_us&edition=fundamental","pubTime":"2025-04-26 03:19","pubTimestamp":1745608779,"startTime":"0","endTime":"0","summary":"US Health and Human Services Secretary Robert Kennedy Jr. said 35 states will participate in a federal pilot program to expand access of costly gene therapies for sickle cell disease to Medicaid patients, multiple news outlets reported Friday.These 35 states house almost 84% of the Medicaid patients with the genetic blood disorder, Bloomberg reported, citing Kennedy's speech to the National Council of Insurance Legislators.The pilot program would also allow the Centers for Medicare and Medicaid Services to arrange payment agreements for the therapies on behalf of states, Bloomberg said.The various states' interest in the pilot program represents \"positive news\" for pharmaceutical companies that manufacture the gene therapies, including Bluebird Bio , Vertex Pharmaceuticals  and Crispr Therapeutics . The companies' therapies, which were approved in December 2023, come with a costly price tag and \"have struggled to gain traction,\" according to Bloomberg.The Department of Health and Human","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRSP","IE00BFTCPJ56.SGD","SG9999013999.USD","LU0079474960.USD","LU0256863811.USD","LU1861559042.SGD","IE00B4R5TH58.HKD","BK4139","IE0002270589.USD","LU0320765992.SGD","LU1035775433.USD","LU2456880835.USD","SG9999001176.SGD","LU1585245621.USD","LU2362541273.HKD","LU0234570918.USD","LU0058720904.USD","LU0823416689.USD","BK4611","LU0109394709.USD","IE00B894F039.SGD","IE00B19Z9Z06.USD","LU0289739699.SGD","BK4556","IE0002141913.USD","LU2462157665.USD","LU2236285917.USD","BK4585","LU0889565916.HKD","LU2417539215.USD","LU1093756325.SGD","IE00B19Z9P08.USD","BK4567","VRTX","LU2324357040.USD","SGXZ57979304.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BZ9MQY76.HKD","BK4578","IE00B19Z3581.USD","LU0061475181.USD","LU0417517546.SGD","LU1093756168.USD","LU2237438978.USD","BLUE","LU1861558580.USD","LU1430594728.SGD","BK4533","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2530136072","title":"Gilead Shares Down 3.6% After Quarterly Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2530136072","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530136072?lang=en_us&edition=fundamental","pubTime":"2025-04-25 21:32","pubTimestamp":1745587936,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4N3R31CJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B3T34201.USD","IE00BZ1G4Q59.USD","LU1571399168.USD","BK4139","IE0002270589.USD","LU0320765992.SGD","LU1585245621.USD","BK4568","LU0234570918.USD","LU0058720904.USD","LU2468319806.SGD","BK4550","LU0109394709.USD","BK4583","LU1839511570.USD","LU2087621335.USD","LU2089984988.USD","LU0289739699.SGD","IE00B7SZLL34.SGD","BK4585","LU1066053197.SGD","LU0889565916.HKD","BK4566","IE00BSNM7G36.USD","BK4578","IE00B19Z3581.USD","IE00BKVL7J92.USD","BK4588","BK4532","LU1430594728.SGD","LU1066051498.USD","GILD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2530183726","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2530183726","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530183726?lang=en_us&edition=fundamental","pubTime":"2025-04-25 18:52","pubTimestamp":1745578338,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD – Research Report), Merit Medi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-684?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-684?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3581.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","BK4568","BK4578","LU0109394709.USD","LU2089984988.USD","LU0234570918.USD","LU1839511570.USD","LU2468319806.SGD","LU0889565916.HKD","BK4588","BK4550","LU0058720904.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","LU2087621335.USD","BK4585","LU1066051498.USD","LU0320765992.SGD","LU1430594728.SGD","LU1066053197.SGD","BK4139","IE0002270589.USD","GILD","IE00B7SZLL34.SGD","LU1571399168.USD","HCSG","BK4566","IE00B3T34201.USD","BK4137","BK4532","IE00BZ1G4Q59.USD","LU1585245621.USD","BK4583"],"gpt_icon":0},{"id":"2530903420","title":"Gilead Shares Down 4.2% Premarket After Quarterly Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2530903420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530903420?lang=en_us&edition=fundamental","pubTime":"2025-04-25 17:13","pubTimestamp":1745572426,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4N3R30Q8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1430594728.SGD","LU1066053197.SGD","LU1585245621.USD","LU1571399168.USD","BK4568","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU0234570918.USD","BK4139","LU1066051498.USD","BK4585","LU0109394709.USD","LU0320765992.SGD","LU2087621335.USD","BK4588","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","GILD","IE00BKVL7J92.USD","LU2468319806.SGD","LU0289739699.SGD","BK4578","IE00B19Z3581.USD","IE0002270589.USD","BK4566","BK4583","IE00B3T34201.USD","LU2089984988.USD","LU0058720904.USD","BK4550","LU1839511570.USD","LU0889565916.HKD","BK4532"],"gpt_icon":0},{"id":"2530527926","title":"Gilead : RBC Raises Target Price to $92 From $89","url":"https://stock-news.laohu8.com/highlight/detail?id=2530527926","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530527926?lang=en_us&edition=fundamental","pubTime":"2025-04-25 13:37","pubTimestamp":1745559472,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R301W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GILD","LU0289739699.SGD","BK4532","BK4583","LU1571399168.USD","BK4139","LU0320765992.SGD","IE00BKVL7J92.USD","LU1585245621.USD","LU1066053197.SGD","LU2087621335.USD","LU2089984988.USD","LU1430594728.SGD","BK4585","BK4588","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BK4578","LU1839511570.USD","LU0109394709.USD","LU0058720904.USD","BK4568","LU2468319806.SGD","IE0002270589.USD","LU1066051498.USD","BK4566","BK4550","LU0889565916.HKD","IE00B3T34201.USD","LU0234570918.USD"],"gpt_icon":0},{"id":"2530458942","title":"Gilead Sciences (GILD) Gets a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530458942","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530458942?lang=en_us&edition=fundamental","pubTime":"2025-04-25 11:55","pubTimestamp":1745553315,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Matthew Biegler from Oppenheimer maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-buy-from-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-buy-from-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4550","LU0109394709.USD","IE00B3T34201.USD","LU1066053197.SGD","IE0002270589.USD","LU1839511570.USD","BK4585","OPY","LU2468319806.SGD","LU0058720904.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","BK4588","BK4127","LU0234570918.USD","LU0320765992.SGD","IE00BKVL7J92.USD","BK4578","BK4568","LU1585245621.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","BK4566","LU2087621335.USD","LU1066051498.USD","LU1571399168.USD","BK4139","BK4583","BK4532","GILD","LU0889565916.HKD","IE00B7SZLL34.SGD","LU1430594728.SGD","LU2089984988.USD"],"gpt_icon":0},{"id":"2530591728","title":"Sui Ecosystem Token Sees Widespread Price Surge, CETUS Up 36% in 24 Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2530591728","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530591728?lang=en_us&edition=fundamental","pubTime":"2025-04-25 09:29","pubTimestamp":1745544540,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 25th, according to CoinGecko data, the Sui ecosystem tokens saw a general price increase, including:CETUS rose by 36% in the past 24 hours, now trading at $0.191NS rose by 17.6% in the past 24 hours, now trading at $0.2261SEND rose by 34.5% in the past 24 hours, now trading at $0.6897NAVX rose by 18.7% in the past 24 hours, now trading at $0.06048BLUE rose by 14.6% in the past 24 hours, now trading at $0.08583SCA rose by 16.2% in the past 24 hours, now trading at $0.1161","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/291160","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4556","BLUE","SCA","BK4578","BK4139"],"gpt_icon":0},{"id":"2530960859","title":"Gilead Q1 Biktarvy Sales $3.15 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2530960859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530960859?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:02","pubTimestamp":1745524922,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nP8N3JT0JZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1430594728.SGD","LU0889565916.HKD","LU0109394709.USD","IE00B7SZLL34.SGD","LU2089984988.USD","LU0289739699.SGD","BK4139","BK4568","LU1066051498.USD","IE00B19Z3581.USD","LU2468319806.SGD","BK4578","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","IE00B3T34201.USD","IE0002270589.USD","LU0320765992.SGD","BK4588","LU0058720904.USD","BK4583","LU0234570918.USD","LU1571399168.USD","IE00B19Z3B42.SGD","LU2087621335.USD","BK4532","BK4550","LU1585245621.USD","LU1839511570.USD","BK4566","LU1066053197.SGD","IE00BSNM7G36.USD","BK4585","GILD"],"gpt_icon":0},{"id":"2530608969","title":"Gilead Outlook 2025 EPS $5.65 - $6.05 VS Prior Guidance $5.95 - $6.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2530608969","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530608969?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:02","pubTimestamp":1745524922,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nP8N3JT0JZ:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1430594728.SGD","LU1066053197.SGD","LU1585245621.USD","LU1571399168.USD","BK4568","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU0234570918.USD","BK4139","LU1066051498.USD","BK4585","LU0109394709.USD","LU0320765992.SGD","LU2087621335.USD","BK4588","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","GILD","IE00BKVL7J92.USD","LU2468319806.SGD","LU0289739699.SGD","BK4578","IE00B19Z3581.USD","IE0002270589.USD","BK4566","BK4583","IE00B3T34201.USD","LU2089984988.USD","LU0058720904.USD","BK4550","LU1839511570.USD","LU0889565916.HKD","BK4532"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":53,"code":"91000000","status":"200"}]}}